Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

<p>Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast Today at 9:00 AM ET REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/soleno-therapeutics-announces-positive-statistically-significant-top-line-results-from-randomized-withdrawal-period-of-study-c602-of-dccr-for-prader-willi-syndrome/">Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>